Relationships & Accomplishments
Sienna Biopharmaceuticals Announces Its Topical, Non-Steroid TrkA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2b Study and Plans to Initiate Phase 3 Psoriasis Trials
December 6, 2018 | Posted in: Relationships & Accomplishments
Sienna Biopharmaceuticals Announces Its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%)
Demonstrated Significant Impact on Psoriasis in Phase 2b Study and Plans to Initiate Phase 3 Psoria... » Read More
Novartis Phase III Study Reduces Cardiovascular Risk
June 27, 2017 | Posted in: Relationships & Accomplishments
Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
Basel, June 22, 2017 –Novartis today announced topline results from ... » Read More
CANVAS Program
June 27, 2017 | Posted in: Relationships & Accomplishments
RE: CANVAS Program main results
We were excited to report the CANVAS Program main results at the recent meeting of the American Diabetes Assoc... » Read More
AMAG Pharmaceuticals, Inc.
May 31, 2017 | Posted in: Relationships & Accomplishments
WALTHAM, Mass., May 2, 2017 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced positive top-line results from a Phase 3 randomized, double-blind, non-inferiority clinical trial evalua... » Read More
Viamet Reports Positive Results from REVIVE
May 31, 2017 | Posted in: Relationships & Accomplishments
Viamet Reports Positive Results from REVIVE Phase 2b Trial of Oral VT-1161 in Recurrent Vulvovaginal Candidiasis
-48 Week Results Demonstrate Strong Clinical Benefit and Very Favorable Safet... » Read More
